<p>Eric Lefkofsky is known to be a successful serial entrepreneur and over the years have started and run many different business ventures. One of his many business ventures that went on to become hugely successful as well as popular is Groupon, which as per current market valuation is net worth over $2 billion. He is also the co-founder of Tempus, which is a healthcare startup that focuses on gathering data in the field of cancer therapies and research.</p>
<p>Tempus helps in gathering cancer treatment related data from various hospitals to help the oncologists and physicians determine why some treatment is more effective on some patient and why it isn’t as effective on others. It factors in the use of genetics as well to help determine the best treatment process possible for the particular patients, which in turn helps in reducing the recovery time of the patients and cancels out the trial and error treatment provided.</p>
<p>Eric Lefkofsky is a self-made billionaire who started Groupon in 2008, which is a platform for the merchants to provide attractive deals to the consumers directly. He went on to start a few of other ventures in the future, which includes data science firm named Uptake Technologies and Lightbank Investments. The Lightbank Investments venture capital firm started by Eric Lefkofsky has investments in over a hundred companies and start-ups including the popular dating application Coffee Meets Bagel and Beachmint and learn more about Eric.</p>
<p>Even though Eric Lefkofsky is not from the medical background, he started Tempus after one of his close family members was diagnosed with breast cancer. During the treatment process, he realized that the doctors do not have any means to understand which treatment or medicines are the most effective. After consulting with some of the most renowned oncologists in the medical and healthcare sector, he realized that the primary issue is the lack of availability of centralized data and Eric’s lacrosse camp.</p>
<p>Tempus fills in this gap in a very efficient manner and has collaborated with many hospitals, cancer specialty clinics, oncologists, and other medical facilities to collect cancer treatment related data. Such data would help in effectively treating cancer, and can potentially help doctors save many lives and more information click here.</p>
The medical field has gained extensively from the contributions of Mikhail Blagosklonny. Out of the numerous praiseworthy discoveries and researches, he has made, patients have benefited a great deal. He mainly specializes in oncology, and Mikhail hopes to make a big difference in the way patients are treated, and the efforts he has put in making new discoveries makes him one of the most prominent members of his profession. Mikhail Blagosklonny’s first discoveries relate to the science of anti-aging and the invention of a drug known as Rapamycin. He virtually owns the patent plus many others across the spectrum of drug discoveries in the US. Follow Mikhail on Google Scholar
Rapamycin is touted to be useful in the management and therapies of various forms of cancers. The chemical analysis and components if the new wonder drug can improve the overall quality of life and extending the life expectancy of many suffer from cancer. Although many doctors and researchers have been working on various formulas for treating cancer, it was not until Mikhail came up with Rapamycin that many patients began experiencing better relief and comfort. It is for that reason that he is highly esteemed in the medical circles. The doctor has an incredible passion and drives to bring a huge difference in the quality of life the people living with cancer lead, and that is why he devotes most of his life’s work to oncological studies.
He is also very devoted to teaching and giving lectures, and for most of his career, he has taught in several prestigious institutions and colleges. He began teaching at the New York School of Medicine immediate after his graduation from medical the medical college. He firmly believes that the best way to give back to the society is to engage in teaching to prepare future scientists and a new generation of first class doctors and researchers. Presently he is a professor in the famous the Roswell Park Cancer Institute. As one of the top teachers in the Institute, he is using his vast experience and knowledge to contribute to new discoveries in the field of oncology. The efforts Dr. Mikhail Blagosklonny has made through research and the voluminous amount of literature he has contributed have positively helped many students at the Institute.
Before coming to the Roswell Park Cancer Institute, he worked for an organization called Ordway. The team was pioneering many studies into the best ways of helping cancer patients. The amount and extent of his involvement in research work have significantly contributed to a new knowledge of the best ways to give cancer therapies. He is noted for the changes in the treatment of cancer that have been adopted by many medical institutions. The conclusions he has arrived at in his research work have convinced him that the forms of treatment used are not adequate. To give a more precise diagnosis and to provide effective treatment, the doctor is advocating for treatment that is geared towards understanding the genetic characteristics of the patients. Most of his works are widely circulate in peer-reviewed journals. Visit classroomvoices.org to read more about Mikhail.
Modern medicine has made many advancements that have improved the quality of human life. It has made diseases that were once very common like polio virtually extinct in many areas of the world and it has made diseases that many people suffer from like sickle cell anemia and HIV/AIDS much more easier to live with than they otherwise would be. But a comprehensive and highly effective cure for cancer continues to outwit much of the medical community. In 2014 the disease took the lives of more than half a million people according to the Centers for Disease Control and Prevention. More than 20 million adults have also been diagnosed with some form of the disease in the United States. One thing that is clear in the battle to beat back the impact of the disease is that doctors need new tools to fight it. Innovation in the world of oncology is necessary if the medical community is to achieve its goal of preventing the disease from taking the lives of more people in this country and around the world.
In 2015 the Rutgers Cancer Institute of New Jersey partnered with a local family to put serious muscle behind laying the groundwork for the development of new and more effective cancer treatments. That year Rutgers University implemented a call to fund endowments for 18 research chairs. The university was seeking $3 million for each of its new chairs.
When it came to funding a chair that would focus on cancer research in the burgeoning field known as precision medicine and genomic science one man stepped up the challenge and pledged half of the amount. Omar Boraie and his relative Sam Boraie decided to pledge $1.5M to launch the Omar Boraie Chair In Genomic Science at the Rutgers Cancer Institute. Dr. Shridar Ganesan who holds both a degree in medicine and a doctorate was named to the Omar Boraie Chair In Genomic Science in 2015. Ganesan’s background in oncology is an extensive and thorough one. According to Newswise Boraie is an oncologist and once worked at a cancer center that was part of Harvard University’s Medical School. Dr. Ganesan’s work in cancer research has earned him acclaim in the international medical community. Bloomberg reveals that because of Boraie’s philanthropic efforts Ganesan will be able to build upon Rutgers Cancer Institute’s groundbreaking work in the precision medicine and genomic science field. The application of genomic science to cancer treatment has the ability to enable oncologists to examine the genetics behind a patient’s cancer and thus better understand it. As Boraie suggested the work that scientists at Rutgers Cancer Institute of New Jersey are doing with genomic science could have potentially far-reaching benefits for cancer patients whose diagnoses are particularly difficult.